Denali Therapeutics IncNASDAQ:DNLI
- LAST PRICE28.5900
- TODAY'S CHANGE (%)-0.0800 (-0.2790%)
- Bid / Lots28.5700/ 1
- Ask / Lots28.6100/ 3
- Open / Previous Close28.3700 / 28.6700
- Day Range
- 52 Week Range
- Volume242,341
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNLI |
|---|---|---|
| 09:32 ET | 9840 | 28.24 |
| 09:34 ET | 1400 | 28.11 |
| 09:36 ET | 1400 | 28.08 |
| 09:38 ET | 1200 | 28.17 |
| 09:39 ET | 1000 | 28.205 |
| 09:41 ET | 1300 | 28.11 |
| 09:43 ET | 800 | 28.04 |
| 09:45 ET | 1000 | 28.12 |
| 09:48 ET | 5007 | 28.15 |
| 09:50 ET | 4276 | 28.155 |
| 09:52 ET | 5335 | 28.295 |
| 09:54 ET | 2565 | 28.24 |
| 09:56 ET | 1900 | 28.175 |
| 09:57 ET | 600 | 28.115 |
| 09:59 ET | 4207 | 28.12 |
| 10:01 ET | 600 | 28.14 |
| 10:03 ET | 1676 | 28.115 |
| 10:06 ET | 300 | 28.125 |
| 10:08 ET | 3796 | 28.19 |
| 10:10 ET | 2132 | 28.24 |
| 10:12 ET | 1500 | 28.3 |
| 10:14 ET | 2301 | 28.31 |
| 10:15 ET | 1600 | 28.24 |
| 10:17 ET | 659 | 28.22 |
| 10:19 ET | 1303 | 28.27 |
| 10:21 ET | 3195 | 28.4 |
| 10:24 ET | 1889 | 28.33 |
| 10:26 ET | 8517 | 28.46 |
| 10:28 ET | 5009 | 28.55 |
| 10:30 ET | 2991 | 28.56 |
| 10:32 ET | 1200 | 28.575 |
| 10:33 ET | 2038 | 28.72 |
| 10:35 ET | 1407 | 28.69 |
| 10:37 ET | 1500 | 28.685 |
| 10:39 ET | 800 | 28.7 |
| 10:42 ET | 1036 | 28.78 |
| 10:46 ET | 300 | 28.94 |
| 10:48 ET | 2328 | 28.86 |
| 10:50 ET | 5325 | 28.785 |
| 10:51 ET | 100 | 28.83 |
| 10:53 ET | 9243 | 28.83 |
| 10:55 ET | 300 | 28.855 |
| 10:57 ET | 800 | 28.85 |
| 11:00 ET | 600 | 28.79 |
| 11:02 ET | 100 | 28.79 |
| 11:04 ET | 300 | 28.835 |
| 11:06 ET | 103 | 28.86 |
| 11:08 ET | 200 | 28.81 |
| 11:09 ET | 1865 | 28.64 |
| 11:11 ET | 500 | 28.645 |
| 11:13 ET | 200 | 28.6 |
| 11:15 ET | 300 | 28.67 |
| 11:20 ET | 200 | 28.7 |
| 11:22 ET | 1087 | 28.73 |
| 11:24 ET | 363 | 28.66 |
| 11:26 ET | 300 | 28.625 |
| 11:31 ET | 215 | 28.61 |
| 11:33 ET | 100 | 28.64 |
| 11:36 ET | 300 | 28.61 |
| 11:38 ET | 1100 | 28.7 |
| 11:40 ET | 465 | 28.72 |
| 11:42 ET | 214 | 28.75 |
| 11:44 ET | 100 | 28.73 |
| 11:45 ET | 100 | 28.72 |
| 11:47 ET | 900 | 28.75 |
| 11:51 ET | 2393 | 28.795 |
| 11:54 ET | 1328 | 28.79 |
| 11:58 ET | 100 | 28.81 |
| 12:02 ET | 500 | 28.83 |
| 12:03 ET | 100 | 28.84 |
| 12:05 ET | 671 | 28.79 |
| 12:09 ET | 837 | 28.77 |
| 12:16 ET | 600 | 28.765 |
| 12:18 ET | 200 | 28.69 |
| 12:20 ET | 1000 | 28.644 |
| 12:21 ET | 1184 | 28.62 |
| 12:23 ET | 300 | 28.63 |
| 12:25 ET | 500 | 28.63 |
| 12:30 ET | 100 | 28.7 |
| 12:32 ET | 710 | 28.66 |
| 12:34 ET | 100 | 28.63 |
| 12:36 ET | 300 | 28.6 |
| 12:38 ET | 415 | 28.575 |
| 12:39 ET | 100 | 28.55 |
| 12:41 ET | 272 | 28.575 |
| 12:45 ET | 500 | 28.545 |
| 12:48 ET | 118 | 28.54 |
| 12:50 ET | 100 | 28.53 |
| 12:52 ET | 635 | 28.54 |
| 12:54 ET | 300 | 28.53 |
| 12:56 ET | 100 | 28.52 |
| 12:57 ET | 200 | 28.53 |
| 12:59 ET | 500 | 28.5 |
| 01:01 ET | 339 | 28.525 |
| 01:03 ET | 100 | 28.52 |
| 01:10 ET | 1300 | 28.465 |
| 01:12 ET | 300 | 28.45 |
| 01:14 ET | 775 | 28.39 |
| 01:15 ET | 1034 | 28.4375 |
| 01:19 ET | 400 | 28.435 |
| 01:21 ET | 200 | 28.48 |
| 01:24 ET | 200 | 28.5 |
| 01:26 ET | 400 | 28.4806 |
| 01:28 ET | 1200 | 28.48 |
| 01:30 ET | 100 | 28.55 |
| 01:32 ET | 700 | 28.48 |
| 01:33 ET | 367 | 28.5468 |
| 01:35 ET | 200 | 28.5 |
| 01:37 ET | 600 | 28.535 |
| 01:39 ET | 600 | 28.56 |
| 01:42 ET | 600 | 28.59 |
Sep 9, 2024
DJ Denali Therapeutics Price Target Maintained With a $35.00/Share by Cantor Fitzgerald, from 11:46AM ET on Monday Sep 09, 2024 by Dow Jones
11:46AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 4, 2024
DJ Denali Therapeutics Is Maintained at Buy by B of A Securities, from 7:47AM ET on Wednesday Sep 04, 2024 by Dow Jones
7:47AM ET on Wednesday Sep 04, 2024 by Dow JonesDJ Denali Therapeutics Price Target Maintained With a $90.00/Share by HC Wainwright & Co., from 7:47AM ET on Wednesday Sep 04, 2024 by Dow Jones
7:47AM ET on Wednesday Sep 04, 2024 by Dow Jones
Sep 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Denali Therapeutics Inc | 4.1B | -10.0x | --- |
CRISPR Therapeutics AG | 3.9B | -14.2x | --- |
Axsome Therapeutics Inc | 4.3B | -14.3x | --- |
ADMA Biologics Inc | 4.6B | 136.3x | --- |
Apellis Pharmaceuticals Inc | 3.4B | -10.1x | --- |
TG Therapeutics Inc | 3.5B | 37.2x | --- |
Company Information
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Contact Information
- Headquarters
- 161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
- Phone
- 650-866-8548
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Vicki Sato
- President, Chief Executive Officer, Director
- Ryan Watts
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Alexander Schuth
- Chief Medical Officer
- Carole Ho
- Director
- Steven Krognes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.1B |
|---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 143.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-2.85 |
Book Value | $7.45 |
P/E Ratio | -10.0x |
Price/Sales (TTM) | 3,239.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -37,938.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
